ArticleThe Journal of experimental medicine2022
A dysregulated sebum-microbial metabolite-IL-33 axis initiates skin inflammation in atopic dermatitis.
Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 85 citations in OpenAlex.
- Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor.Cell reports. Medicine · 2026Trial
- Preclinical and clinical studies on Qin-Zhu-Liang-Xue decoction: insights from network pharmacology and implications for atopic dermatitis treatment.Frontiers of medicine · 2025Trial
- Postbiotic Metabolites: Therapeutic Potential, Industrial Applications, Market Dynamics, and Regulatory Frameworks.Probiotics and antimicrobial proteins · 2026Review
- Article
- From Barrier Disruption and Immune Dysregulation to Targeted Therapies in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Update on environmental determinants of allergic diseases.The Journal of allergy and clinical immunology · 2026Review
- Keratinocytes: A key player in skin immunity and their emerging roles in secondary lymphedema.JID innovations : skin science from molecules to population health · 2026Review
- Acetate uptake alleviates propionate-mediated growth restriction inInfection and immunity · 2026Article
- Lipid droplet-mediated macrophage reprogramming drives fibroblast activation in keloid-associated inflammation.Cell communication and signaling : CCS · 2026Article
- Regulation of allergies across the body by microbial metabolites.Experimental & molecular medicine · 2026Review
- Extracellular wax ester biosynthesis by staphylococcal lipases detoxifies skin fatty acids and shapes interspecies competition.The ISME journal · 2026Article
- Microbiota-directed therapies for atopic dermatitis: a three-tier framework for inflammation control, immune modulation, and microbiome restoration.Frontiers in immunology · 2026Review
- Skin microbiome and cutaneous aging mechanisms and clinical implications.Frontiers in microbiology · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
- Microbiota-driven epigenetic programming of local immunity.Frontiers in immunology · 2026Review
- Novel Anti-Inflammatory Bioactive Peptide Derived from Yak Bone Collagen Alleviates the Skin Inflammation of Mice by Inhibiting the NF-κB Signaling Pathway and Modulating Skin Microbiota.Foods (Basel, Switzerland) · 2025Article
- Skin-lung axis in the atopic march: The immune link from skin to lungs.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Activation of the aryl hydrocarbon receptor relieves acute pancreatitis via the RBX1/HSF1 pathway.Journal of inflammation (London, England) · 2025Article
- Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis.British journal of cancer · 2025Article
- Skin microbiota in atopic dermatitis: victim or executioner?Clinical microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
Microbial dysbiosis in the skin has been implicated in the pathogenesis of atopic dermatitis (AD); however, whether and how changes in the skin microbiome initiate skin inflammation, or vice versa, remains poorly understood. Here, we report that the levels of sebum and its microbial metabolite, propionate, were lower on the skin surface of AD patients compared with those of healthy individuals. Topical propionate application attenuated skin inflammation in mice with MC903-induced AD-like dermatitis by inhibiting IL-33 production in keratinocytes, an effect that was mediated through inhibition of HDAC and regulation of the AhR signaling pathway. Mice lacking sebum spontaneously developed AD-like dermatitis, which was improved by topical propionate application. A proof-of-concept clinical study further demonstrated the beneficial therapeutic effects of topical propionate application in AD patients. In summary, we have uncovered that the dysregulated sebum-microbial metabolite-IL-33 axis might play an initiating role in AD-related skin inflammation, thereby highlighting novel therapeutic strategies for the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.